Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 8/20 | 0.45 |
| ▸ | ACACA | Q13085 | 5/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | CKS1B | P61024 | 1/20 | 0.40 |
| ▸ | SKP1 | P63208 | 1/20 | 0.40 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30030494 | 1.00 | ACACB (0.45) | ACACBACACAFNTAFNTBCKS1B | |
| SCHEMBL27094493 | 0.83 | P2RX7 (0.39) | — | |
| SCHEMBL27094573 | 0.83 | P2RX7 (0.39) | — | |
| SCHEMBL30031899 | 0.80 | ACACB (0.43) | ACACBACACAFNTAFNTBCKS1B | |
| SCHEMBL30031343 | 0.79 | ACACB (0.45) | ACACBACACAFNTAFNTBCKS1B | |
| SCHEMBL30030597 | 0.76 | ACACB (0.40) | ACACBACACAFNTAFNTBCKS1B | |
| SCHEMBL30030896 | 0.76 | ACACB (0.40) | ACACBACACAFNTAFNTBCKS1B | |
| SCHEMBL30030986 | 0.76 | ACACB (0.40) | ACACBACACAFNTAFNTBCKS1B | |
| SCHEMBL30030516 | 0.74 | ACACB (0.44) | ACACBACACAFNTAFNTBCKS1B | |
| SCHEMBL29142419 | 0.74 | ACACB (0.44) | ACACBACACAFNTAFNTBCKS1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035379-A1 | BICYCLIC PYRIDINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2026-02-05 | — | — | US | disclosed |
| US-12534475-B2 | Bicyclic pyridine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2026-01-27 | — | — | US | disclosed |
| US-12077546-B2 | Bicyclic pyridine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2024-09-03 | — | — | US | disclosed |
| US-20240228505-A1 | BICYCLIC PYRIDINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240150370-A1 | BICYCLIC PYRIDINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4324834-A1 | BICYCLIC PYRIDINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2024-02-21 | — | — | EP | disclosed |
| WO-2022215754-A1 | BICYCLIC PYRIDINE DERIVATIVE | 住友ファーマ株式会社 | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035379-A1 | BICYCLIC PYRIDINE DERIVATIVE | CBR1, CBR3, CYP2B6 | ACACB 2159/4885ACACA 2405/4885FNTA 4515/4885 |
| US-20240228505-A1 | BICYCLIC PYRIDINE DERIVATIVE | CBR1, CBR3, CYB5R3 | ACACB 3045/4885ACACA 3529/4885FNTA 4791/4885 |
| US-12077546-B2 | Bicyclic pyridine derivative | CBR1, CBR3, CYB5R3 | ACACB 3045/4885ACACA 3529/4885FNTA 4791/4885 |
| US-20240150370-A1 | BICYCLIC PYRIDINE DERIVATIVE | CBR1, CBR3, CYB5R3 | ACACB 3045/4885ACACA 3529/4885FNTA 4791/4885 |
| US-12534475-B2 | Bicyclic pyridine derivative | CBR1, CYP2B6, CBR3 | ACACB 1948/4885ACACA 2220/4885FNTA 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.